moxidectin
MOXIDECTIN (moxidectin) is moxidectin, a macrocyclic lactone, is an anthelmintic drug [see microbiology ( )] . First approved in 2018.
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
Moxidectin is an oral tablet anthelmintic agent belonging to the macrocyclic lactone class of drugs. It is indicated for parasitic infections treatable by anthelmintic mechanisms. The drug works by disrupting neuromuscular function in parasitic organisms, leading to paralysis and elimination.
Product approaching loss of exclusivity with moderate competitive pressure (25% intensity); brand team may be transitioning to generic optimization or lifecycle extension strategies.
Moxidectin, a macrocyclic lactone, is an anthelmintic drug [see Microbiology ( )] .
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Pediatric Pharmacokinetics And Safety Study Of Moxidectin
Study Evaluating The Co-Administration Of Moxidectin And Midazolam In Healthy Subjects
Study Evaluating The Effect Of High-Fat Meal On Bioavailability And Pharmacokinetics Of Single Dose Of Moxidectin
Study Evaluating The Excretion Of Moxidectin Into The Breast Milk Of Lactating, Non-Breastfeeding Women
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Patent cliff in ~2 years — expect lifecycle management and generic defense hiring
Moxidectin currently has zero linked job openings and is approaching loss of exclusivity, indicating limited hiring and career growth on the brand team. Professionals considering this product should expect declining commercial headcount and focus on generic transition, market access, and cost-containment strategies rather than growth-stage brand building.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo